Posted on January 9, 2021 by Sitemaster
As we advised readers yesterday, a newly published study by Gregg et al. from the M. D. Anderson Cancer Center has given some clear indications that men diagnosed with lower-risk forms of prostate cancer who are initially managed on active surveillance (AS) can benefit — in terms of time to disease progression — from what is known as the Mediterranean-type diet. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, disease, Mediterranean, progression, risk, surveillance | 4 Comments »
Posted on January 8, 2021 by Sitemaster
The abstract of a newly published study on the use of the Mediterranean diet (MD) by men on active surveillance (AS) for management of low-risk, localized prostate cancer states that … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, low risk, Mediterranean, surveillance | 4 Comments »
Posted on December 22, 2020 by Sitemaster
Last week, I looked at a retrospective study of metastasis-directed therapy (MDT) at the Mayo Clinic among oligorecurrent patients (see this link). … READ MORE …
Filed under: Management, Treatment | Tagged: lymph, metastasis, node, oligorecurrent, radiation, salvage, therapy | 4 Comments »
Posted on December 18, 2020 by Sitemaster
Earlier today, the US Food and Drug Administration (FDA) approved relugolix, (Orgovyx, from Myovant Sciences), the first, oral luteinizing hormone releasing hormone (LHRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antagonist, GnRH, LHRH, Myovant, Orgovyx, relugolix | 6 Comments »
Posted on December 11, 2020 by Sitemaster
Oligometastases in Bones
Metastasis-directed therapy (MDT) when there are only a few bone metastases (called “oligometastatic”) is controversial. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ologometastasis, radiation, recurrent, survival | 6 Comments »
Posted on December 4, 2020 by Sitemaster
OK … so it took us a couple of days to work out why only two centers (at UCSF and UCLA) had been approved to administer the new (to the US) gallium-68 PSMA-11 scans. It wasn’t very smart of us. We should have realized immediately! … READ MORE …
Filed under: Management | Tagged: gallium-68, maunfacture, PSMA, scan | 10 Comments »
Posted on December 3, 2020 by Sitemaster
If you are one of our readers who is really “into” the underlying causes of and development of prostate cancer, then you probably want to see if you can read a newly published article in this week’s New England Journal of Medicine. … READ MORE …
Filed under: Uncategorized | Tagged: epigenetics, evolution, genetrics, initiation, progression | 2 Comments »
Posted on December 2, 2020 by Sitemaster
Yesterday the US Food and Drug Administration (FDA) gave its approval for the first gallium-68 prostate-specific membrane antigen imaging agent (Ga-67 PSMA-11), for the use in association with positron emission tomography (PET) scanning for the evaluation of men with suspected prostate cancer — and most particularly for those men with high-risk characteristics suggesting the possibility of metastasis, including men with newly diagnosed or recurrent disease. However, here’s the “but”… READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: gallium-68, imaging, PET, PSMA, scan | 5 Comments »
Posted on November 25, 2020 by Sitemaster
Some 18 months ago we had written about the possible occurrence of spontaneous remissions in men on active surveillance (AS) for low-risk forms of prostate cancer. We were therefore very interested in a recent article closely related to this topic. … READ MORE..
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, biopsy, negative, remission, serial, spontaneous, surveillance | 14 Comments »
Posted on November 17, 2020 by Sitemaster
If you are someone who can spare a few bucks to support research into prostate cancer (and particularly the more aggressive forms of prostate cancer), please read on … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: donate, PCF, research | Leave a comment »
Posted on November 16, 2020 by Sitemaster
A recent report in the CDC’s Morbidity and Mortality Weekly Report (MMWR) may offer one of the best analyses of an increasing risk for diagnosis with and death from advanced forms of prostate cancer over the period from 2003 to 2017 (the last year for which we have accurate data from the SEER database). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: CDC, Diagnosis, epidemiology, incidence, mortality, risk | 3 Comments »
Posted on November 13, 2020 by Sitemaster
Posted on November 13, 2020 by Sitemaster
The following article was written by two of the founders of Active Surveillance Patients International (ASPI) under the title “Al Roker’s forecast: rising PSA and a radical prostatectomy” and distributed largely by e-mail. It is re-posted here with the permission of the authors. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: active, celebrity, Roker, surveillance | 4 Comments »
Posted on November 12, 2020 by Sitemaster
So our good friend Howard Wolinsky has just written up his assessment on the evolution of the use of the PSA test in “screening” for prostate cancer in an article on the MedPage Today web site. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: PSA, risk, screening, test | 17 Comments »
Posted on October 28, 2020 by Sitemaster
Perhaps unsurprisingly, your sitemaster was a little distracted on March 9 this year (by both the start of the COVID-19 chaos and by his birthday) and so he utterly missed what appears to be a rather important paper on the use of 5α-reductase inhibitors (5-ARIs) in men on active surveillance (AS) for management of low-risk forms of prostate cancer.
… READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 5-ARI, active, AS, Prevention, progression, surveillance | 2 Comments »
